| 查看: 616 | 回复: 3 | |||
[交流]
西替利嗪在儿童用药的主要风险是什么?
|
|
西替利嗪用于儿童,不同资料说法不一:包括“不推荐用于6岁以下儿童”,“不推荐用于12岁以下儿童”,“2岁以下儿童禁用”,“可用于儿童及妊娠或哺乳的妇女”不一而足。 目前权威的说法是? 西替利嗪在儿童用药的主要风险是什么? 希望有最新资料的站友给予解释 |
» 猜你喜欢
博士招生
已经有5人回复
夜,静悄悄的
已经有8人回复
国自科送审了吗
已经有8人回复
收到国自然专家邀请后几年才会有本子送过来评
已经有5人回复
研究生做的很差,你们会让毕业吗?
已经有6人回复
26年博士申请自荐-电催化
已经有5人回复
2026博士或科研助理转27年博士
已经有5人回复
26年申博自荐-计算机视觉
已经有4人回复
» 本主题相关价值贴推荐,对您同样有帮助:
转:用创新承载梦想--扬子江药业致力新品名品开发研制巡礼
已经有15人回复
【转帖】强生制药双阴影:召回局未了,质量门添忧
已经有0人回复
» 抢金币啦!回帖就可以得到:
香港城市大学 数据科学系+能源与环境学院 李堂华 课题组诚招全奖博士/博士后/研究助理
+3/192
国自然申报交流祈福
+4/134
东南大学废弃碳资源利用团队(杰青/海优团队)博士后、科研助理及27级博士生招募
+1/128
招聘科研助理
+1/82
山东征女友,坐标济南
+1/70
双一流高校-南京林业大学-化学工程学院-国家海外优青团队招2026级博士(5月15号截止)
+1/49
急招-华南理工大学-26秋季博士生-生物质材料及电池方向
+1/29
暨南大学中医学院邓力课题组博士后招聘【中西医结合/交叉学科方向】
+1/16
2026年西安交通大学博士招生!
+1/16
吉林大学任雷课题组招机器人和触觉传感方向2026年入学博士生
+1/9
注册小木虫周年大礼包
+1/5
河北工业大学人工智能与数据科学学院刘卫朋课题组招收2026年考察-审核制博士
+1/5
求推荐计算化学/材料计算/AI for Chemistry方向博士课题组(偏理论/计算)
+1/5
上海交通大学复合材料研究所招聘博士后
+1/4
类器官/器官芯片 华西医院有编制研究员招聘
+1/4
英国伦敦布鲁内尔大学高薪招聘欧盟玛丽居里全奖博士
+1/3
科研新人必看:立项/开题/报奖都绕不开科技查新
+1/2
浙江农林大学 林业工程/木材科学与技术方向拟招录一名2026级博士
+1/2
大湾区大学-中山大学联培博士招生(电磁方向)
+1/1
双一流天津工业大学电信学院李鸿强教授招收2026年申请审核制博士
+1/1
2楼2011-07-13 14:49:57
3楼2011-07-13 21:28:14
★
qinhy(金币+1): 谢谢回帖交流~ 2011-07-14 17:55:39
qinhy(金币+1): 谢谢回帖交流~ 2011-07-14 17:55:39
|
以下是国外网站的资料,显示对6个月以上儿童进行过安全性评价,应该可以使用。 国外上市的有片剂、糖浆剂和咀嚼片。 ZYRTEC (cetirizine) can be taken without regard to food consumption. ZYRTEC (cetirizine) is available as 5 mg and 10 mg tablets, 1 mg/mL syrup, and 5 mg and 10 mg chewable tablets which can be taken with or without water. Adults and Children 12 Years and Older: The recommended initial dose of ZYRTEC (cetirizine) is 5 mg or 10 mg per day in adults and children 12 years and older, depending on symptom severity. Most patients in clinical trials started at 10 mg. ZYRTEC (cetirizine) is given as a single daily dose. The time of administration may be varied to suit individual patient needs. Children 6 to 11 Years: The recommended initial dose of ZYRTEC (cetirizine) in children aged 6 to 11 years is 5 mg or 10 mg once daily depending on symptom severity. The time of administration may be varied to suit individual patient needs. Children 2 to 5 Years: The recommended initial dose of ZYRTEC (cetirizine) in children aged 2 to 5 years is 2.5 mg (? teaspoon) syrup once daily. The dosage in this age group can be increased to a maximum dose of 5 mg per day given as 1 teaspoon syrup once a day or one ? teaspoon syrup given every 12 hours, or one 5 mg chewable tablet once a day. Children 6 months to <2 years: The recommended dose of ZYRTEC (cetirizine) syrup in children 6 months to 23 months of age is 2.5 mg (? teaspoon) once daily. The dose in children 12 to 23 months of age can be increased to a maximum dose of 5 mg per day, given as ? teaspoon (2.5 mg) every 12 hours. Syrup is recommended for children under the age of 2 years. Pediatric Use: The safety of ZYRTEC (cetirizine) has been demonstrated in pediatric patients aged 6 months to 11 years. The safety of ZYRTEC (cetirizine) , at daily doses of 5 or 10 mg, has been demonstrated in 376 pediatric patients aged 6 to 11 years in placebo-controlled trials lasting up to four weeks and in 254 patients in a non-placebo-controlled 12-week trial. The safety of cetirizine has been demonstrated in 168 patients aged 2 to 5 years in placebo-controlled trials of up to 4 weeks duration. On a mg/kg basis, most of the 168 patients received between 0.2 and 0.4 mg/kg of cetirizine HCl. The safety of cetirizine in 399 patients aged 12 to 24 months has been demonstrated in a placebo-controlled 18-month trial, in which the average dose was 0.25 mg/kg bid, corresponding to a range of 4 to 11 mg/day. The safety of ZYRTEC (cetirizine) syrup has been demonstrated in 42 patients aged 6 to 11 months in a placebo-controlled 7-day trial. The prescribed dose was 0.25 mg/kg bid, which corresponded to a mean of 4.5 mg/day, with a range of 3.4 to 6.2 mg/day. The effectiveness of ZYRTEC (cetirizine) for the treatment of allergic rhinitis and chronic idiopathic urticaria in pediatric patients aged 6 months to 11 years is based on an extrapolation of the demonstrated efficacy of ZYRTEC (cetirizine) in adults with these conditions and the likelihood that the disease course, pathophysiology and the drug's effect are substantially similar between these two populations. Efficacy is extrapolated down to 6 months of age for perennial allergic rhinitis and down to 2 years of age for seasonal allergic rhinitis because these diseases are thought to occur down to these ages in children. The recommended doses for the pediatric population are based on cross-study comparisons of the pharmacokinetics and pharmacodynamics of cetirizine in adult and pediatric subjects and on the safety profile of cetirizine in both adult and pediatric patients at doses equal to or higher than the recommended doses. The cetirizine AUC and Cmax in pediatric subjects aged 6 to 23 months who received a mean of 2.3 mg in a single dose, and in subjects aged 2 to 5 years who received a single dose of 5 mg of cetirizine syrup and in pediatric subjects aged 6 to 11 years who received a single dose of 10 mg of cetirizine syrup were estimated to be intermediate between that observed in adults who received a single dose of 10 mg of cetirizine tablets and those who received a single dose of 20 mg of cetirizine tablets. The safety and effectiveness of cetirizine in pediatric patients under the age of 6 months have not been established. Last reviewed on RxList: 5/17/2007 This monograph has been modified to include the generic and brand name in many instances. 别人的回复,贴到这,与同道共享 |
4楼2011-07-14 10:35:31












回复此楼